Journal
CLINICAL INFECTIOUS DISEASES
Volume 34, Issue 8, Pages 1129-1136Publisher
UNIV CHICAGO PRESS
DOI: 10.1086/339542
Keywords
-
Categories
Funding
- NIAID NIH HHS [AI-27663, AI-27660, 2 U01 AI-38855, 5 UO1 AI-27658] Funding Source: Medline
- NIEHS NIH HHS [T32 ES07142-18] Funding Source: Medline
- NIMH NIH HHS [P30 MH59037] Funding Source: Medline
Ask authors/readers for more resources
High-level adherence to regimens of combination antiretroviral therapy and prophylactic medications for opportunistic infections (OIs) is crucial to their success. However, little is known about the association between adherence to these life-sustaining therapies and such clinical outcomes as progression of acquired immune deficiency syndrome (AIDS) or development of OIs. We assessed adherence to regimens of antiretroviral and Mycobacterium avium complex (MAC) prophylactic medications in 643 patients enrolled in a trial of MAC prophylaxis. By week 56 of the study follow-up, 42% of the patients reported nonadherence to MAC prophylaxis, whereas one-quarter of the patients reported nonadherence to potent antiretroviral regimens. Nonadherence to both MAC prophylaxis and antiretroviral therapy was associated with higher human immunodeficiency virus (HIV) type 1 RNA levels and a significant increase in the risk of developing an AIDS-defining complication or death. Predictors of nonadherence are presented. These results underscore the clinical significance of adherence to HIV therapy and may be helpful in designing interventions to optimize the management of HIV by improving adherence.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available